ArticleThe Journal of biological chemistry2020
Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1
Erratum issuedOpen access · hybridAbstract read
In one paragraph
Article in The Journal of biological chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 13 citations in OpenAlex.
- Advancing neurofibromatosis research: a comparative review of animal models and their utility in dissecting the tumor microenvironment.Laboratory animal research · 2026Review
- Decreased PP2A expression and activity represent a therapeutic target for plexiform neurofibroma.Acta neuropathologica communications · 2026Article
- Metabolic and behavioral effects of neurofibromin result from differential recruitment of MAPK and mTOR signaling.PLoS genetics · 2026Article
- Rac1 in gastric cancer: a molecular driver of invasion, EMT, and therapeutic resistance.Journal of translational medicine · 2025Review
- Regulation of Ras p21 and RalA GTPases activity by quinine in mammary epithelial cells.Molecular and cellular biochemistry · 2024Article
- Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.Nature communications · 2024Article
- Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform Neurofibroma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- RAS and beyond: the many faces of the neurofibromatosis type 1 protein.Disease models & mechanisms · 2022Article
- SSMD: a semi-supervised approach for a robust cell type identification and deconvolution of mouse transcriptomics data.Briefings in bioinformatics · 2021Article
- Increased nuclear translation of YAP might act as a potential therapeutic target for NF1-related plexiform neurofibroma.International journal of medical sciences · 2021Observational
- Emerging mechanism and therapeutic potential of neurofibromatosis type 1-related nerve system tumor: Advancing insights into tumor development.Neuro-oncology advancesReview
Corrections and comments
- Erratum issued
Authors and funding
16 authors at 1 institution in 1 country.
Julie A MundDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
SuJung ParkDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
Abbi E SmithDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
Yongzheng HeDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
Li JiangDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
Eric HawleyDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
Michelle J RobersonDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
Dana K MitchellDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.ORCID 0000-0002-1022-1072
Mohannad Abu-SultanahDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
Jin YuanDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
Waylan K BesslerDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
George SanduskyDivision of Pediatric Hematology-Oncology, Indiana University School of Medicine, Indianapolis, Indiana.
Shi ChenDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
Chi ZhangDepartment of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana.
Steven D RhodesDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana.
D Wade ClappDepartment of Pediatrics, Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana dclapp@iu.edu.
Indiana University School of Medicine
Funding
Pediatric Scientist Development Program (PSDP) [K12]K12HD000850 · NICHD · YALE UNIVERSITY · PI Sallie R. Permar · 1987 to 2026
$44.1MProject 4: Secondary Cancers Among NF1 Cancer SurvivorsU54CA196519 · NCI · INDIANA UNIVERSITY INDIANAPOLIS · PI Yunlong Liu · 2015 to 2026
$26.9MREGULATION OF HEMATOPOIETIC CELL PRODUCTIONT32DK007519 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI KAPLAN, MARK H · 1986 to 2020
$7.1MF-box ubiquitin ligases destabilize neurofibrominR01NS104489 · NINDS · INDIANA UNIVERSITY INDIANAPOLIS · PI CLAPP, DAVID W · 2018 to 2022
$1.7MNCI NIH HHS U54 CA196519NICHD NIH HHS K12 HD000850NIDDK NIH HHS T32 DK007519NINDS NIH HHS R01 NS104489
Abstract
Neurofibromatosis type 1 (NF1) is a common cancer predisposition syndrome caused by mutations in the
Indexed as
Gene Knockdown TechniquesNeoplasms, Second PrimaryNeurofibroma, PlexiformNeurofibromatosis 1AnimalsMiceMice, KnockoutNeurofibromin 1NeuropeptidesProto-Oncogene Masrac1 GTP-Binding ProteinMAS1 protein, humanNeurofibromin 1NeuropeptidesProto-Oncogene Masrac1 GTP-Binding ProteinRac1 protein, mouseanimal modelGTPase-activating protein (GAP)kinase signalingneurofibromatosis type 1Ras-related C3 botulinum toxin substrate 1 (Rac1)Schwann cellsshort hairpin RNA (shRNA)tumor cell biologytumor suppressor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.